Gene:
CALU
calumenin

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CALU

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1043550 NC_000007.13:g.128409225A>G, NC_000007.14:g.128769171A>G, NG_033110.1:g.34880A>G, NM_001130674.2:c.*4A>G, NM_001199671.1:c.*4A>G, NM_001199672.1:c.*4A>G, NM_001199673.1:c.*77A>G, NM_001219.4:c.*4A>G, NR_074086.1:n.678A>G, XM_011516588.1:c.*4A>G, rs11545537, rs17475700, rs3183116, rs61381822
A > -
A > G
SNP
No VIP available No Clinical Annotations available VA
rs11653 NC_000007.13:g.128409580T>A, NC_000007.14:g.128769526T>A, NG_033110.1:g.35235T>A, NM_001130674.2:c.*359T>A, NM_001199671.1:c.*359T>A, NM_001199672.1:c.*359T>A, NM_001199673.1:c.*432T>A, NM_001219.4:c.*359T>A, NR_074086.1:n.1033T>A, XM_011516588.1:c.*359T>A, rs1043570, rs11545533, rs17475721, rs3183137, rs3807311
T > -
T > A
SNP
No VIP available No Clinical Annotations available VA
rs2290228 NC_000007.13:g.128388648G>A, NC_000007.14:g.128748594G>A, NG_033110.1:g.14303G>A, NM_001130674.2:c.11G>A, NM_001199671.1:c.35G>A, NM_001199672.1:c.35G>A, NM_001199673.1:c.11G>A, NM_001219.4:c.11G>A, NP_001124146.1:p.Arg4Gln, NP_001186600.1:p.Arg12Gln, NP_001186601.1:p.Arg12Gln, NP_001186602.1:p.Arg4Gln, NP_001210.1:p.Arg4Gln, NR_074086.1:n.141+9162G>A, XM_011516588.1:c.-406G>A, rs10399443, rs11545532, rs61408000
G > A
SNP
R4Q
No VIP available CA VA
rs339097 NC_000007.13:g.128399224A>G, NC_000007.14:g.128759170A>G, NG_033110.1:g.24879A>G, NM_001130674.2:c.582+133A>G, NM_001199671.1:c.606+133A>G, NM_001199672.1:c.606+133A>G, NM_001199673.1:c.582+133A>G, NM_001219.4:c.582+133A>G, NR_074086.1:n.308+133A>G, XM_011516588.1:c.360+133A>G, rs1668425, rs386582001, rs56844598
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA26047

Details

Cytogenetic Location: chr7 : q32.1 - q32.1
GP mRNA Boundary: chr7 : 128379346 - 128413477
GP Gene Boundary: chr7 : 128369346 - 128416477
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Warfarin Pathway, Pharmacodynamics
    Simplified diagram of the target of warfarin action and downstream genes and effects.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GGCX
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
OPN1SW

Curated Information ?

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart valve replacement

Publications related to CALU: 17

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?. Clinical medicine & research. 2013. Glurich Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic drug monitoring. 2012. Lee Kyung-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012. Ramirez Andrea H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. Pharmacogenomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. European journal of clinical pharmacology. 2011. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis. 2011. Luxembourg Baete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of thrombosis and haemostasis : JTH. 2010. Lubitz S A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Voora D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. European journal of clinical pharmacology. 2010. Cadamuro Janne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. Journal of thrombosis and haemostasis : JTH. 2007. González-Conejero R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of warfarin dose with genes involved in its action and metabolism. Human genetics. 2007. Wadelius Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thrombosis and haemostasis. 2006. Vecsler Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. The Journal of biological chemistry. 2004. Wajih Nadeem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed

LinkOuts

HuGE:
CALU
Comparative Toxicogenomics Database:
813
ModBase:
O43852
HumanCyc Gene:
HS05201
HGNC:
1458

Common Searches